0
Il n'y a pas de produit dans le panier !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Accueil > IL-5

IL-5

Brief Information

Name:Interleukin-5
Target Synonym:T-cell replacing factor,IL5,Interleukin 5,Eosinophil Differentiation Factor,Colony-Stimulating Factor, Eosinophil,B-Cell Differentiation Factor I,Interleukin-5,IL-5,TRF,Interleukin 5 (Colony-Stimulating Factor, Eosinophil),B Cell Differentiation Factor I,EDF
Number of Launched Drugs:2
Number of Drugs in Clinical Trials:8
Lastest Research Phase:Approved

Licensing

Project Name Modality Therapeutic Area Indications Stage Right Available
IL5 mAb Monospecific antibody Immunological disease Asthma Phase II Global  (except China)

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

IL5-H5214-Cell-based assay
 IL-5 CELL

Human IL-5 Protein, premium grade (Cat. No. IL5-H5214) stimulates proliferation of 293F-STAT5/Luc-IL5RA-CD131-9 cells. The specific activity of Human IL-5 Protein, premium grade is > 3.00ⅹ10^6 IU/mg, which is calibrated against human IL-5 WHO International Standard (NIBSC code: 90/586) (QC tested).

IL5-H52H3-Cell-based assay
 IL-5 CELL

Human IL-5 Protein, His Tag (Cat. No. IL5-H52H3) stimulates proliferation of Human IL-5 R alpha/CD131 (Luc) HEK293 Reporter Cell. The typically EC50 for this effect is 3.909 ng/mL (QC tested).

IL5-H52H3-BLI
 IL-5 BLI

Loaded Human IL-5 Protein, His Tag (Cat. No. IL5-H52H3) on NTA Biosensor, can bind Human IL-5 R alpha, Fc Tag with an affinity constant of 4.63 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

EP-128-ELISA
IL-5[Biotinylated]:IL-5Rα Inhibitor Screening ELISA KitIL-5[Biotinylated]:IL-5Rα Inhibitor Screening ELISA Kit (Cat. No. EP-128) ELISA bioactivity

INHIBITION OF IL-5 [BIOTINYLATED]: IL-5 R ALPHA BINDING BY Human IL-5
Serial dilutions of Human IL-5(Catalog # EP128-C03) (1:1 serial dilution, from 10 μg/mL to 0.020 μg/mL (666.67-0.65 nM)) was added into IL-5 R alpha: IL-5-Biotin binding reactions. The assay was performed according to the above-described protocol. Background was subtracted from data points prior to log transformation and curve fitting (QC tested).

Synonym Name

IL-5,TRF,IL5,Interleukin-5

Background

Interleukin 5 (IL5) is an interleukin produced by type-2 T helper cells and mast cells. IL-5 is a 115-amino acid (in human, 133 in the mouse) -long TH2 cytokine that is part of the hematopoietic family. Unlike other members of this cytokine family (namely interleukin 3 and GM-CSF), this glycoprotein in its active form is a homodimer. Interleukin-5 has long been associated with the cause of several allergic diseases including allergic rhinitis and asthma, wherein a large increase in the number of circulating, airway tissue, and induced sputum eosinophils have been observed. Given the high concordance of eosinophils and, in particular, allergic asthma pathology, it has been widely speculated that eosinophils have an important role in the pathology of this disease. Drugs that target IL-5 are mepolizumab and reslizumab.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Reslizumab TRFK-5; CDP-835; SCH-5570; CEP-38072; CTx-55700; SCH-55700 Approved Teva Pharmaceutical Industries Ltd Cinqair, Cinquil, Cinqaero United States Asthma Teva Respiratory Llc 2016-03-23 Hypereosinophilic Syndrome; Loiasis; Pulmonary Eosinophilia; Eosinophilic Esophagitis; Asthma; Bronchitis Details
Mepolizumab SB-240563; 240563 Approved Glaxosmithkline Plc Bosatria, Nucala, 美泊利珠单抗 United States Asthma Glaxosmithkline Llc 2015-11-04 Granulomatosis with Polyangiitis; Hypereosinophilic Syndrome; Eosinophilic Granulomatosis With Polyangiitis; Nasal Polyps; Eosinophilia; Chronic Urticaria; Nose Diseases; Virus Diseases; Eosinophilic Esophagitis; Sinusitis; Asthma; Bronchitis; Pulmonary Disease, Chronic Obstructive; Fasciitis; Dermatitis, Atopic; Angioedema Details
Reslizumab TRFK-5; CDP-835; SCH-5570; CEP-38072; CTx-55700; SCH-55700 Approved Teva Pharmaceutical Industries Ltd Cinqair, Cinquil, Cinqaero United States Asthma Teva Respiratory Llc 2016-03-23 Hypereosinophilic Syndrome; Loiasis; Pulmonary Eosinophilia; Eosinophilic Esophagitis; Asthma; Bronchitis Details
Mepolizumab SB-240563; 240563 Approved Glaxosmithkline Plc Bosatria, Nucala, 美泊利珠单抗 United States Asthma Glaxosmithkline Llc 2015-11-04 Granulomatosis with Polyangiitis; Hypereosinophilic Syndrome; Eosinophilic Granulomatosis With Polyangiitis; Nasal Polyps; Eosinophilia; Chronic Urticaria; Nose Diseases; Virus Diseases; Eosinophilic Esophagitis; Sinusitis; Asthma; Bronchitis; Pulmonary Disease, Chronic Obstructive; Fasciitis; Dermatitis, Atopic; Angioedema Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Recombinant anti-IL-5 humanized monoclonal antibody (Shanghai CP Guojian) 610; SSGJ-610 Phase 3 Clinical Sunshine GuoJian Pharmaceutical (Shanghai) Co Ltd Autoimmune Diseases; Asthma Details
SHR-1703 SHR-1703 Phase 3 Clinical Suzhou Suncadia Biopharmaceuticals Co Ltd, Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd Eosinophilic Granulomatosis With Polyangiitis; Asthma Details
Depemokimab GSK-294; GSK3511294; GSK294; GSK-3511294 Phase 3 Clinical Glaxosmithkline Plc Hypereosinophilic Syndrome; Eosinophilic Granulomatosis With Polyangiitis; Nasal Polyps; Vasculitis; Asthma; Eosinophilic Granuloma; Sinusitis Details
long-acting anti-IL-5 mAb (GSK) Phase 1 Clinical Glaxosmithkline Plc Asthma Details
KBL-693 KBL-693 Phase 1 Clinical Kobiolabs Asthma Details
Mepolizumab biosimilar(Bio Thera Solutions) BAT2606; BAT-2606 Phase 1 Clinical Bio-Thera Solutions Ltd Nasal Polyps; Autoimmune Diseases; Sinusitis; Asthma Details
RC-1416 Phase 1 Clinical Nanjing Rongjiekang Biotechnology Co Ltd Asthma Details
Mepolizumab biosimilar (CTTQ Pharma) Phase 1 Clinical Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group Granulomatosis with Polyangiitis; Hypereosinophilic Syndrome; Vasculitis; Nasal Polyps; Asthma; Eosinophilic Granuloma; Sinusitis; Lymphohistiocytosis, Hemophagocytic Details
Recombinant anti-IL-5 humanized monoclonal antibody (Shanghai CP Guojian) 610; SSGJ-610 Phase 3 Clinical Sunshine GuoJian Pharmaceutical (Shanghai) Co Ltd Autoimmune Diseases; Asthma Details
SHR-1703 SHR-1703 Phase 3 Clinical Suzhou Suncadia Biopharmaceuticals Co Ltd, Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd Eosinophilic Granulomatosis With Polyangiitis; Asthma Details
Depemokimab GSK-294; GSK3511294; GSK294; GSK-3511294 Phase 3 Clinical Glaxosmithkline Plc Hypereosinophilic Syndrome; Eosinophilic Granulomatosis With Polyangiitis; Nasal Polyps; Vasculitis; Asthma; Eosinophilic Granuloma; Sinusitis Details
long-acting anti-IL-5 mAb (GSK) Phase 1 Clinical Glaxosmithkline Plc Asthma Details
KBL-693 KBL-693 Phase 1 Clinical Kobiolabs Asthma Details
Mepolizumab biosimilar(Bio Thera Solutions) BAT2606; BAT-2606 Phase 1 Clinical Bio-Thera Solutions Ltd Nasal Polyps; Autoimmune Diseases; Sinusitis; Asthma Details
RC-1416 Phase 1 Clinical Nanjing Rongjiekang Biotechnology Co Ltd Asthma Details
Mepolizumab biosimilar (CTTQ Pharma) Phase 1 Clinical Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group Granulomatosis with Polyangiitis; Hypereosinophilic Syndrome; Vasculitis; Nasal Polyps; Asthma; Eosinophilic Granuloma; Sinusitis; Lymphohistiocytosis, Hemophagocytic Details

This web search service is supported by Google Inc.

totop

Laisser un message